Navigation Links
TetraLogic Appoints Jonathan B. Lloyd Jones as Chief Financial Officer and Vice President Corporate Development
Date:6/8/2011

MALVERN, Pa., June 8, 2011 /PRNewswire/ -- TetraLogic Pharmaceuticals, a biopharmaceutical company developing novel small molecule Smac mimetic drugs to treat cancer, today announced the appointment of Mr. Jonathan B. Lloyd Jones, ACA, MBA, as chief financial officer and vice president of corporate development.

Mr. Lloyd Jones joins TetraLogic with over 25 years of corporate development and finance experience.  He has led negotiations, valuation and diligence teams that developed and executed over $2 billion of biotechnology and pharmaceutical company mergers and acquisitions, financing and licensing transactions. At TetraLogic, Mr. Lloyd Jones will lead the company's corporate development and financing strategies as well as the negotiation and execution of related transactions.

From 2006 to 2010, Mr. Lloyd Jones served as vice president of finance at TransMolecular, Inc. During the prior 10 years, he was employed by Genzyme as a senior director of corporate development. Earlier in his career Mr. Lloyd Jones was employed by the Royal Bank of Scotland (Nassau). Mr. Lloyd Jones holds a master of business administration from The Wharton School of the University of Pennsylvania and is a member of the Institute of Chartered Accountants in England & Wales.

About TetraLogic Pharmaceuticals

TetraLogic Pharmaceuticals is a privately held biopharmaceutical company that focuses on the discovery and development of Smac mimetics, small molecule drugs that mimic Smac (Second mitochondrial-derived activator of caspases) for the treatment of cancers. The company's institutional investors include Clarus Ventures, HealthCare Ventures, Quaker BioVentures, Novitas Capital, Nextech Invest Ltd, Hatteras Venture Partners, Pfizer Ventures, Latterell Venture Partners, the Vertical Group, Amgen Ventures, and Kammerer Associates. For additional information, please refer to the company's Web site at www.tetralogicpharma.com.

Media Contact:

Russo Partners, LLC
Tony Russo, Ph.D., or Andreas Marathovouniotis
212-845-4251 or 212-845-5235
tony.russo@russopartnersllc.com
andreas.marathis@russopartnersllc.com

TetraLogic Pharmaceuticals
James Goldschmidt, Ph.D.
610-889-9900


'/>"/>
SOURCE TetraLogic Pharmaceuticals
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. TetraLogic Closes $23 Million Second Tranche of Series C Financing
2. TetraLogic Closes $6 Million Series C-1 Investment with Nextech Invest Ltd.
3. Quark Pharmaceuticals Appoints New Chief Medical Officer
4. West Pharmaceutical Services, Inc. Appoints New Director
5. PAREXEL Expands Late Phase Clinical Research Services and Appoints Leading Pharmacoepidemiology Expert Victor Kiri
6. Curemark Appoints Preeminent Pediatrics Gastroenterologist
7. CVBT Appoints Dr. Nabil Dib as Principal Investigator for Phase II Heart Trial
8. Ardea Biosciences Appoints John W. Beck Chief Financial Officer, Announces Clinical Development Progress and Reports First Quarter 2008 Financial Results
9. Cytopia Appoints Study Chairman for JAK2 Clinical Trial
10. Enobia Pharma Appoints Industry Veterans with Commercial and Manufacturing Expertise to Expand Senior Management Team
11. NovaRx Appoints Industry Veteran as President and COO
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2017)... 22, 2017 AVACEN Medical (AVACEN) announced that ... successfully helping those with the widespread pain associated with ... Amanda in Essex, England commented, ... hair, experiencing no sleep at all, tremendous pain, with ... cannot recommend [the AVACEN 100] enough, how this has ...
(Date:9/18/2017)... 18, 2017 EpiVax, Inc. ("EpiVax") ... and immune engineering, today announced a new ... (H7N9) vaccine. ... influenza and presents a challenge for traditional ... to be effective. Using state-of-the-art bioinformatics and molecular ...
(Date:9/12/2017)... 2017  ValGenesis Inc., the global leader in ... to announce the appointment of Dr. Ajaz ... of Directors and Chairman of Advisory Board beginning ... companies to manage their entire validation lifecycle process ... this process. Furthermore, ValGenesis VLMS enables rigorous compliance, ...
Breaking Medicine Technology:
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... PurhealthRX ... CBD Oil utilizing Purzorb™ technology. Applying the Purzorb™process to full spectrum CBD oil will ... and providing a CBD form that can be easily incorporated into liquid products, while ...
(Date:10/13/2017)... ... October 13, 2017 , ... The Visiting Nurse Association (VNA) of Somerset ... of specialty vendors and unique items from across the nation, this holiday-themed event will ... services offered by the VNA. The boutique will be open Saturday, November 4 ...
(Date:10/13/2017)... ... October 13, 2017 , ... ... Software Development, has been awarded a contract by the Center for Medicare and ... aims to accelerate the enterprise use of Agile methodologies in a consistent and ...
(Date:10/12/2017)... ... October 12, 2017 , ... Planet Fitness, one of ... announced today its plans to open a flagship location in Covington, LA at 401 ... Rooms To Go store next to Office Depot in the Holiday Square shopping center. ...
(Date:10/12/2017)... ... October 12, 2017 , ... Information about the technology: ... develop to enable prevention of a major side effect of chemotherapy in children. ... pediatric patients. For cisplatin, hearing loss is FDA listed on-label as a dose ...
Breaking Medicine News(10 mins):